[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624947":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":11,"responsibleParty":35,"collaborators":11,"id":38,"slug":11,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":11,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":11,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":11},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"trastuzumab-rezetecan group","EXPERIMENTAL",null,[13],"Drug: Trastuzumab rezetecan",{"label":15,"type":16,"description":11,"interventionNames":17},"trastuzumab deruxtecan group","ACTIVE_COMPARATOR",[18],"Drug: Trastuzumab deruxtecan",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Trastuzumab rezetecan","Participants will receive Trastuzumab-rezetecan for 8 cycles",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Trastuzumab deruxtecan","Participants will receive Trastuzumab deruxtecan for 8 cycles",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Zhenzhen Liu","CONTACT","13603862755","zlyyliuzhenzhen0800@zzu.edu.cn",{"type":36,"investigatorFullName":31,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Professor","100624947",false,"NCT07416253","Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer","A Randomized, Open-Label, Phase II Study Comparing the Efficacy and Safety of Trastuzumab-rezetecan and Trastuzumab Deruxtecan (T-DXd) in Neoadjuvant Treatment of Patients With HER2-Positive Early or Locally Advanced Breast Cancer","Inclusion Criteria:\n\n1. Female, 18-75 years old, treatment-naive\n2. ECOG PS 0-1\n3. Histologically confirmed HER2+ (IHC 3+ or IHC 2+\u002FISH+) early\u002Flocally advanced breast cancer (AJCC 8th: cT2-cT4 any N cM0) or cT1c N+ cM0; known ER\u002FPR status\n4. Adequate organ function (hematology\u002Fbiochemistry\u002Fcoagulation\u002Furine\u002Fcardiac)\n5. Negative pregnancy test (childbearing women); agree to effective contraception\n6. Sign an informed consent form.\n\nExclusion Criteria:\n\n1. Bbilateral\u002Finflammatory\u002Foccult breast cancer.\n2. Prior anti-tumor therapy (chemotherapy\u002Fradiotherapy\u002Ftargeted therapy, etc.); radical radiotherapy (4 weeks prior) or palliative radiotherapy (2 weeks prior) to first dose.\n3. Concurrent anti-tumor therapy; other malignancies (within past 5 years, except cured basal cell carcinoma\u002Fcervical CIS).\n4. Prior trial participation (past 4 weeks); systemic immunosuppressants\u002Fhormones (\\>10 mg\u002Fday prednisone equivalent, 2 weeks prior; nasal\u002Finhaled steroids excluded).\n5. Live\u002Fattenuated vaccine (past 4 weeks); major non-breast surgery (4 weeks prior, incomplete recovery).\n6. Active\u002Frelapsing autoimmune disease (except controlled hypothyroidism\u002Fwell-managed skin diseases\u002Ftype 1 diabetes); immunodeficiency (HIV+\u002Forgan transplant).\n7. Uncontrolled cardiovascular\u002Fcerebrovascular disease (e.g., MI\u002Fstroke in 6 months, NYHA III-IV heart failure, QTcF \\>470 msec \\[female\\]).\n8. Active ILD\u002Fsevere lung disease; active hepatitis B (HBsAg+ \\& HBV DNA ≥500 IU\u002FmL)\u002Fhepatitis C (HCV RNA+); severe infection requiring anti-infective therapy.\n9. Bleeding\u002Fthrombotic tendency; hypersensitivity to study drugs\u002Fexcipients.\n10. Pregnant\u002Flactating women; women of childbearing potential with positive pregnancy test or refusing contraception.\n11. Other conditions (e.g., uncontrolled hypertension\u002Fdiabetes, neuropsychiatric disorders) deemed unsuitable by the investigator.","FEMALE","18 Years","75 Years",{"count":48,"type":49},68,"ESTIMATED","INTERVENTIONAL",[52],"PHASE2","This is a single-center, randomized, open-label, phase II interventional study. Eligible patients will be randomized 1:1 to receive either Trastuzumab-rezetecan (4.8 mg\u002Fkg Q3W) or T-DXd (5.4 mg\u002Fkg Q3W) for 8 neoadjuvant cycles. After completing neoadjuvant treatment, patients will undergo definitive surgery, and tpCR will be assessed from resected specimens. Patients will then be followed up to monitor long-term efficacy (e.g., EFS) and late-onset adverse events. A total of 68 patients (34 per arm) will be enrolled to achieve the study's statistical objectives.",[55],"Breast Cancer",[57,58],"HER2 positive","Antibody-drug conjugate","NOT_YET_RECRUITING","2026-02-10",{"date":62,"type":63},"2026-02-18","ACTUAL",{"date":65,"type":49},"2026-03",{"date":67,"type":49},"2030-07",{"name":5,"class":6}]